行情

ABUS

ABUS

Arbutus生物制药
NASDAQ

实时行情|Nasdaq Last Sale

3.430
-0.130
-3.65%
盘后: 3.360 -0.07 -2.04% 19:59 08/13 EDT
开盘
3.450
昨收
3.560
最高
3.470
最低
3.260
成交量
465.31万
成交额
--
52周最高
9.02
52周最低
0.8214
市值
2.78亿
市盈率(TTM)
-1.3935
分时
5日
1月
3月
1年
5年

分析师评级

6位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测ABUS价格均价为5.17,最高价位8.00,最低价为1.000。

EPS

ABUS 新闻

更多
Is Arbutus Biopharma (ABUS) Outperforming Other Medical Stocks This Year?
Is (ABUS) Outperforming Other Medical Stocks This Year?
Zacks · 3天前
Arbutus Bio slides 10% as Q2 trails consensus; reiterates cash burn guidance
Arbutus Biopharma (ABUS) Q2 results: Revenues: $1.5M (+114.3%). Net loss: ($17.1M) (+34.5%); loss/share: ($0.25) (+45.7%). CF Ops: ($24.3M) (+28.9%). Phase
seekingalpha · 6天前
Arbutus Biopharma EPS misses by $0.01, misses on revenue
Arbutus Biopharma (NASDAQ:ABUS): Q2 GAAP EPS of -$0.25 misses by $0.01. Revenue of $1.51M (+132.3% Y/Y) misses by $0.33M. Shares +3.2% PM. Press Release
seekingalpha · 6天前
Arbutus Biopharma (ABUS) Reports Q2 Loss, Lags Revenue Estimates
Arbutus (ABUS) delivered earnings and revenue surprises of -8.70% and -17.94%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 6天前
Recap: Arbutus Biopharma Q2 Earnings
Shares of Arbutus Biopharma (NASDAQ:ABUS) fell 1% in pre-market trading after the company reported Q2 results.Quarterly Results Earnings per share rose 45.65% over the past year to ($0.25), which missed the estimate of ($0.24).Revenue of $1,514,000 up by 116.2
Benzinga · 6天前
Arbutus Reports Second Quarter 2020 Financial Results and Provides Corporate Update
Phase 1a/1b clinical trial for AB-729, a subcutaneously delivered RNAi agent, remains on track with results from additional cohorts expected in the second half of 2020 AB-836, an oral capsid inhibitor, remains on track for completion of IND enabling studies b
GlobeNewswire · 6天前
Arbutus to Present at Wedbush PacGrow Healthcare Virtual Conference
WARMINSTER, Pa., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies t
GlobeNewswire · 08/05 12:00
Will Arbutus Biopharma (ABUS) Report Negative Earnings Next Week? What You Should Know
Arbutus (ABUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 07/31 16:30

所属板块

制药
-0.45%
制药与医学研究
-0.06%

热门股票

代码
价格
涨跌幅

ABUS 简况

Arbutus Biopharma Corp是一家临床阶段的生物制药公司。该公司致力于发现、开发和商业化治疗慢性乙型肝炎病毒(HBV)感染者的疗法。其产品线专注于寻找治疗慢性HBV感染的联合用药方案,目的是开发一套干预病毒生命周期中的不同点并重新激活宿主免疫系统的产品。它正在开发一种产品线,该产品线由具有互补作用机制的多种候选药物组成。该公司的HBV产品线包括核糖核酸(RNA)干扰(RNAi)治疗剂、口服衣壳抑制剂、抑制程序性死亡配体1(PDL1)的口服化合物和口服HBV RNA稳定消除剂。该公司的子公司包括Arbutus Inc和Arbutus Biopharma US Holdings, Inc.。
展开

微牛提供Arbutus Biopharma Corp(NASDAQ-ABUS)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的ABUS股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易ABUS股票基本功能。